267 related articles for article (PubMed ID: 23683667)
41. Serenoa repens in benign prostatic hypertrophy: analysis of 2 Italian studies.
Mantovani F
Minerva Urol Nefrol; 2010 Dec; 62(4):335-40. PubMed ID: 20944533
[TBL] [Abstract][Full Text] [Related]
42. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia.
Bernichtein S; Pigat N; Camparo P; Latil A; Viltard M; Friedlander G; Goffin V
Prostate; 2015 May; 75(7):706-22. PubMed ID: 25683150
[TBL] [Abstract][Full Text] [Related]
43. A randomized double-blind placebo controlled phase I-II study on clinical and molecular effects of dietary supplements in men with precancerous prostatic lesions. Chemoprevention or "chemopromotion"?
Gontero P; Marra G; Soria F; Oderda M; Zitella A; Baratta F; Chiorino G; Gregnanin I; Daniele L; Cattel L; Frea B; Brusa P
Prostate; 2015 Aug; 75(11):1177-86. PubMed ID: 25893930
[TBL] [Abstract][Full Text] [Related]
44. Serenoa repens associated with Urtica dioica (ProstaMEV) and curcumin and quercitin (FlogMEV) extracts are able to improve the efficacy of prulifloxacin in bacterial prostatitis patients: results from a prospective randomised study.
Cai T; Mazzoli S; Bechi A; Addonisio P; Mondaini N; Pagliai RC; Bartoletti R
Int J Antimicrob Agents; 2009 Jun; 33(6):549-53. PubMed ID: 19181486
[TBL] [Abstract][Full Text] [Related]
45. A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia.
Hizli F; Uygur MC
Int Urol Nephrol; 2007; 39(3):879-86. PubMed ID: 17203353
[TBL] [Abstract][Full Text] [Related]
46. Can the effect of antibiotherapy and anti-inflammatory therapy on serum PSA levels discriminate between benign and malign prostatic pathologies?
Erol H; Beder N; Calişkan T; Dündar M; Unsal A; Culhaci N
Urol Int; 2006; 76(1):20-6. PubMed ID: 16401916
[TBL] [Abstract][Full Text] [Related]
47. Non-hormonal treatment for male infertility: the potential role of Serenoa repens, selenium and lycopene.
Cannarella R; Calogero AE; Condorelli RA; Giacone F; Mongioi' LM; La Vignera S
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(7):3112-3120. PubMed ID: 31002161
[TBL] [Abstract][Full Text] [Related]
48. The Effect of a Pure Anti-inflammatory Therapy on Reducing Prostate-specific Antigen Levels in Patients Diagnosed With a Histologic Prostatitis.
Gallo L
Urology; 2016 Aug; 94():198-203. PubMed ID: 27208818
[TBL] [Abstract][Full Text] [Related]
49. Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.
Iacono F; Prezioso D; Illiano E; Ruffo A; Romeo G; Amato B
BMC Surg; 2012; 12 Suppl 1(Suppl 1):S22. PubMed ID: 23173650
[TBL] [Abstract][Full Text] [Related]
50. Botanical derivatives for the prostate.
Cristoni A; Di Pierro F; Bombardelli E
Fitoterapia; 2000 Aug; 71 Suppl 1():S21-8. PubMed ID: 10930709
[TBL] [Abstract][Full Text] [Related]
51. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay.
Vela Navarrete R; Garcia Cardoso JV; Barat A; Manzarbeitia F; López Farré A
Eur Urol; 2003 Nov; 44(5):549-55. PubMed ID: 14572753
[TBL] [Abstract][Full Text] [Related]
52. Effectiveness on urinary symptoms and erectile function of Prostamev Plus® vs only extract Serenoa repens.
Marzano R; Dinelli N; Ales V; Bertozzi MA
Arch Ital Urol Androl; 2015 Mar; 87(1):25-7. PubMed ID: 25847892
[TBL] [Abstract][Full Text] [Related]
53. [The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia].
Aliaev IuG; Vinarov AZ; Demidko IuL; Spivak LG
Urologiia; 2013; (4):32-6. PubMed ID: 24159762
[TBL] [Abstract][Full Text] [Related]
54. CD4+ and CD8+ T-lymphocyte scores cannot reliably predict progression in patients with benign prostatic hyperplasia.
Lamb AD; Qadan M; Roberts S; Timlin H; Vowler SL; Campbell FM; Grigor K; Bartlett JM; McNeill SA
BJU Int; 2011 Jul; 108(2 Pt 2):E43-50. PubMed ID: 21457430
[TBL] [Abstract][Full Text] [Related]
55. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro.
Latil A; Libon C; Templier M; Junquero D; Lantoine-Adam F; Nguyen T
BJU Int; 2012 Sep; 110(6 Pt B):E301-7. PubMed ID: 22520557
[TBL] [Abstract][Full Text] [Related]
56. [Morphological changes in prostatic tissue of patients with benign prostatic hyperplasia treated with permixon].
Sivkov AV; Kudriavtsev IuV; Medvedev AA; Razumov SV; Kochetov SA
Urologiia; 2004; (5):10-6. PubMed ID: 15560155
[TBL] [Abstract][Full Text] [Related]
57. [Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study].
Popa G; Hägele-Kaddour H; Walther C
MMW Fortschr Med; 2005 Oct; 147 Suppl 3():103-8. PubMed ID: 16261945
[TBL] [Abstract][Full Text] [Related]
58. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
59. Role of AgNOR count and its correlation with serum PSA levels in prostatic lesions.
Goel T; Garg S
Urol Int; 2009; 82(3):286-90. PubMed ID: 19440015
[TBL] [Abstract][Full Text] [Related]
60. Progression delay in men with mild symptoms of bladder outlet obstruction: a comparative study of phytotherapy and watchful waiting.
Djavan B; Fong YK; Chaudry A; Reissigl A; Anagnostou T; Bagheri F; Waldert M; Fajkovic H; Marihart S; Harik M; Spaller S; Remzi M
World J Urol; 2005 Sep; 23(4):253-6. PubMed ID: 16175413
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
